Investors Research Corp bought a new position in shares of Pfizer (NYSE:PFE) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 22,985 shares of the biopharmaceutical company’s stock, valued at approximately $833,000.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Venturi Wealth Management LLC increased its position in Pfizer by 3.6% during the 4th quarter. Venturi Wealth Management LLC now owns 164,093 shares of the biopharmaceutical company’s stock worth $5,943,000 after purchasing an additional 5,747 shares during the period. Aevitas Wealth Management Inc. acquired a new position in Pfizer during the 4th quarter worth approximately $282,000. Oakview Capital Management L.P. increased its position in Pfizer by 13.0% during the 4th quarter. Oakview Capital Management L.P. now owns 752,510 shares of the biopharmaceutical company’s stock worth $27,256,000 after purchasing an additional 86,383 shares during the period. Amalgamated Bank increased its position in Pfizer by 9.7% during the 4th quarter. Amalgamated Bank now owns 746,688 shares of the biopharmaceutical company’s stock worth $27,045,000 after purchasing an additional 66,202 shares during the period. Finally, Assetmark Inc. increased its position in Pfizer by 68.7% during the 4th quarter. Assetmark Inc. now owns 74,415 shares of the biopharmaceutical company’s stock worth $2,695,000 after purchasing an additional 30,301 shares during the period. Institutional investors own 69.53% of the company’s stock.
In related news, CEO Ian C. Read sold 132,312 shares of the company’s stock in a transaction that occurred on Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total value of $4,764,555.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Douglas M. Lankler sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $36.89, for a total value of $1,844,500.00. Following the completion of the sale, the insider now directly owns 133,057 shares in the company, valued at approximately $4,908,472.73. The disclosure for this sale can be found here. In the last ninety days, insiders sold 380,349 shares of company stock worth $13,829,340. 0.06% of the stock is owned by corporate insiders.
PFE has been the topic of several research analyst reports. SunTrust Banks reissued a “hold” rating and set a $40.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Jefferies Group set a $39.00 price target on Pfizer and gave the stock a “hold” rating in a research note on Monday, February 26th. Morningstar set a $38.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. BMO Capital Markets set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Finally, Bank of America set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and an average price target of $40.08.
PFE stock opened at $35.97 on Thursday. Pfizer has a 1 year low of $31.67 and a 1 year high of $39.43. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.98 and a current ratio of 1.27. The company has a market capitalization of $213.11 billion, a P/E ratio of 13.57, a P/E/G ratio of 1.78 and a beta of 0.89.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.03. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The firm had revenue of $12.91 billion for the quarter, compared to analyst estimates of $13.14 billion. During the same quarter in the prior year, the company earned $0.69 EPS. Pfizer’s revenue was up 1.0% on a year-over-year basis. analysts expect that Pfizer will post 2.95 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, May 11th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.78%. The ex-dividend date of this dividend is Thursday, May 10th. Pfizer’s payout ratio is currently 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.